Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology · 2026
Risk of Cardiovascular and Cerebrovascular Diseases in Patients with Myeloid Neoplasms: Results from 1.8 Million Inhabitants of Northwest Italy.
СтатьяНазвание и аннотация: Перевод в очереди
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Catalano Alberto, Bonuomo Valentina, Grano Selene, Dhupdale Tanisha Satish, Bianchi Alex, Dansero Lucia, Gnavi Roberto, Sacerdote Carlotta, Fava Carmen, Ricceri Fulvio
Аннотация
BACKGROUND: Myeloid neoplasms are a group of pathologies characterized by clonal hematopoiesis and genetic mutations, often associated with inflammation and cardiovascular (CV) risk. Whereas targeted therapies have improved prognosis, they may also lead to CV adverse effects. The aim was to analyze the risk of developing CV or cerebrovascular disease (CVD) events in patients who received a diagnosis of myeloid neoplasm, considering four subgroups of myeloid neoplasms: chronic myeloid leukemia, myeloproliferative neoplasm, myelodysplastic syndromes (MDS), and acute myeloid leukemia.
METHODS: Data were obtained from the Piedmont Longitudinal Study, including all subjects present in the census conducted in October 2011 and who were 40 to 80 years old. The association between myeloid neoplasms and CV and/or cerebrovascular diseases was evaluated through competing risks analyses, both on the entire sample and considering 40- to 64- and 65- to 80-year-old subgroups.
RESULTS: Of 1,795,216 subjects, 1,395 received a diagnosis of myeloid neoplasm and 82,978 experienced CVDs. Patients with myeloid neoplasms exhibited different CVD risks. In the younger population, CLM resulted associated with cerebrovascular events and MDS with myocardial infarction. In the older patients, chronic myeloid leukemia was associated with heart failure, acute myeloid leukemia with CVD events, MDS with CV, particularly heart failure and peripheral vascular disease, and cerebrovascular events, and myeloproliferative neoplasm with CV events, especially peripheral vascular disease.
CONCLUSIONS: The results highlighted the importance of implementing a specific CVD prevention and surveillance plan for patients with myeloid neoplasms.
IMPACT: Study evidence underlines which myeloid neoplasm patient subgroups require increased attention and monitoring to prevent future CVD events.
METHODS: Data were obtained from the Piedmont Longitudinal Study, including all subjects present in the census conducted in October 2011 and who were 40 to 80 years old. The association between myeloid neoplasms and CV and/or cerebrovascular diseases was evaluated through competing risks analyses, both on the entire sample and considering 40- to 64- and 65- to 80-year-old subgroups.
RESULTS: Of 1,795,216 subjects, 1,395 received a diagnosis of myeloid neoplasm and 82,978 experienced CVDs. Patients with myeloid neoplasms exhibited different CVD risks. In the younger population, CLM resulted associated with cerebrovascular events and MDS with myocardial infarction. In the older patients, chronic myeloid leukemia was associated with heart failure, acute myeloid leukemia with CVD events, MDS with CV, particularly heart failure and peripheral vascular disease, and cerebrovascular events, and myeloproliferative neoplasm with CV events, especially peripheral vascular disease.
CONCLUSIONS: The results highlighted the importance of implementing a specific CVD prevention and surveillance plan for patients with myeloid neoplasms.
IMPACT: Study evidence underlines which myeloid neoplasm patient subgroups require increased attention and monitoring to prevent future CVD events.